SION-638 is under clinical development by Sionna Therapeutics and currently in Phase I for Cystic Fibrosis. According to GlobalData, Phase I drugs for Cystic Fibrosis have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SION-638’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SION-638 is under development for the treatment of cystic fibrosis (CF) with F508del genetic mutations. The therapeutic candidate is a small molecule that acts by targeting the nucleotide-binding domain (NBD1) of cystic fibrosis transmembrane conductance regulator (CFTR).
Sionna Therapeutics overview
Sionna Therapeutics (Sionna) is a developer of novel small molecule therapies to treat cystic fibrosis (CF). Sionna is headquartered in Natick, Massachusetts, the US.
For a complete picture of SION-638’s drug-specific PTSR and LoA scores, buy the report here.